All News
  • All News
  • In the News
  • Press Releases
  • Publications
  • Events
  • Video
  • Noteworthy Articles

Immunexpress Saving Lives with Improved Sepsis Diagnosis: Interview with Rolland Carlson PhD, CEO

Medgadget editor Tom Peach sat down with Dr.Carlson from Immunexpress to hear more about the company’s first FDA-approved sepsis diagnostic test, SeptiCyte, and what the future of sepsis diagnosis and treatment may look like.  
2nd World Sepsis Conference Banner

Immunexpress is proud to be one of the sponsors for the 2nd World Sepsis Conference, Sept 5-6, 2018

"The 2nd World Sepsis Congress will be held on September 5th and 6th, 2018 - free of charge and completely online, so you can participate from wherever you have an internet connection. Over the course of 17 sessions, more than 100 speakers from 30 countries will discuss all aspects of...
Health Leaders

3 Need-to-Know Leaps in Sepsis Care

Rolland Carlson, PhD, CEO of Immunexpress, discusses a different approach to the sepsis battle. Rather than passively chasing pathogens, the Company has developed a test to measure the body's specific immune response to infection by examining biomarkers in the patient's blood.
MedTech Insight

Immunexpress is a finalist for the 2018 MedTech Best Proof-of-Value of an Innovation award

"LONDON – AUGUST 13, 2018 – Informa Pharma Intelligence today announces the finalists for the 2018 Medtech Insight Awards. The diverse group of finalists were chosen by a highly respected independent panel of experts from across the sector." -- Pharma Intelligence

Immunexpress Receives Notice of U.S. Patent Allowance for SeptiCyte™ Technology to Quantify Biomarkers

The allowance complements the Company's growing patent portfolio of gene technology in the detection of host response to sepsis SEATTLE, July 26, 2018 /PRNewswire/ -- Immunexpress, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application No. 15/160749, "Validating biomarker...

Appointments and advancements – Fayyaz Memon

Immunexpress continues executive team expansion with addition of Fayyaz Memon as VP of Regulatory Affairs & Quality.

Immunexpress Continues Executive Team Expansion with Addition of Fayyaz Memon as VP of Regulatory Affairs & Quality

SEATTLE, July 10, 2018 /PRNewswire/ -- Immunexpress, Inc. today announced that Fayyaz Memon, MBA, MS, has joined the company's Executive Team as Vice President of Regulatory Affairs and Quality. "Mr. Memon arrives at a key time for the Company as we continue to fortify our leadership team with accomplished individuals well-versed in the life sciences...
genome web

People in the News: Rolland Carlson, Tanja Dowe, Katleen Verleysen

Accomplished industry leaders join recently appointed CEO, Dr. Rolland Carlson, to expand on the comprehensive experience of the Board.

Appointments and advancements – Rolland Carlson, Tanja Dowe, Katleen Verleysen

Immunexpress strengthens Board of Directors with key appointments.

Immunexpress Strengthens Board of Directors with Key Appointments

Accomplished Industry Leaders Join Recently Appointed CEO, Dr. Rolland Carlson, to Expand on the Comprehensive Experience of the Board SEATTLE, May 15, 2018 /PRNewswire/ -- Immunexpress, Inc. today announced the appointment of three new members to its Board of Directors. Rolland Carlson, PhD, Tanja Dowe and Katleen Verleysen, PhD, have joined the company's board, while Bea Arnold, PhD, has stepped...
pulmonary advisor

Molecular Laboratory Test Can Discriminate Sepsis From Noninfectious SIRS

Design and results of clinical trials that led to FDA clearance of SeptiCyte™ LAB published in the American Journal of Respiratory and Clinical Care Medicine.

Product Briefs – SeptiCyte LAB

Immunexpress, Inc. published in the American Journal of Respiratory and Clinical Care Medicine the design and results of clinical trials validating SeptiCyte™ LAB in the discrimination of sepsis from non-infectious systemic inflammatory response syndrome (SIRS) in the Intensive Care Unit (ICU) of hospitals.

If you are a member of the media, please contact:

Maggie Beller
Russo Partners
(646) 942-5631